Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 39 entries
View as:

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Phase: N/A Priority: Normal
NCT ID: NCT04546724 Org: User:
Start: 09/17/20 End: 10/15/21 Due: 10/15/22

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Phase: N/A Priority: Normal
NCT ID: NCT00604708 Org: User:
Start: 09/30/05 End: 09/30/06 Due: 09/30/07

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT02316470 Org: User:
Start: 12/31/14 End: 10/31/15 Due: 10/31/16

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Phase: N/A Priority: Normal
NCT ID: NCT00605085 Org: User:
Start: 10/31/05 End: 11/30/06 Due: 11/30/07

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Phase: N/A Priority: Normal
NCT ID: NCT01041573 Org: User:
Start: 03/31/10 End: 07/31/11 Due: 07/31/12

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

Phase: N/A Priority: Normal
NCT ID: NCT04838444 Org: User:
Start: 04/02/21 End: 05/31/31 Due: 05/31/32

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04786444 Org: User:
Start: 02/22/21 End: 01/26/22 Due: 01/26/23

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Phase: N/A Priority: Normal
NCT ID: NCT01047839 Org: User:
Start: 01/31/10 End: 08/31/13 Due: 08/31/14

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Phase: N/A Priority: Normal
NCT ID: NCT01559831 Org: User:
Start: 06/30/12 End: 03/31/13 Due: 03/31/14

Safety Surveillance After Immunization With IXIARO

Phase: N/A Priority: Normal
NCT ID: NCT01335412 Org: User:
Start: 03/31/11 End: 06/30/13 Due: 06/30/14

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Phase: N/A Priority: Normal
NCT ID: NCT00776230 Org: User:
Start: 09/30/08 End: 06/30/10 Due: 06/30/11

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03382964 Org: User:
Start: 03/05/18 End: 07/28/19 Due: 07/28/20

COVID-19 Paediatric VLA2001-321 Study

Phase: N/A Priority: Normal
NCT ID: NCT05298644 Org: User:
Start: 10/01/22 End: 08/30/25 Due: 08/30/26

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

Phase: N/A Priority: Normal
NCT ID: NCT05364242 Org: User:
Start: 05/09/22 End: 05/22/23 Due: 05/22/24

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Phase: N/A Priority: Normal
NCT ID: NCT00595270 Org: User:
Start: 10/31/05 End: 04/30/09 Due: 04/30/10

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT03425149 Org: User:
Start: 02/24/18 End: 11/16/18 Due: 11/16/19

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Phase: N/A Priority: Normal
NCT ID: NCT00594958 Org: User:
Start: 09/30/06 End: 09/30/07 Due: 09/30/08

An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

Phase: N/A Priority: Normal
NCT ID: NCT01296386 Org: User:
Start: 12/31/10 End: 04/30/13 Due: 04/30/14

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Phase: N/A Priority: Normal
NCT ID: NCT00595790 Org: User:
Start: 09/30/05 End: 11/30/07 Due: 11/30/08

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Phase: N/A Priority: Normal
NCT ID: NCT00596102 Org: User:
Start: 10/31/05 End: - Due: -

Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04671017 Org: User:
Start: 12/16/20 End: 04/06/22 Due: 04/06/23

A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

Phase: N/A Priority: Normal
NCT ID: NCT06028841 Org: User:
Start: 04/10/24 End: 08/27/24 Due: 08/27/25

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

Phase: N/A Priority: Normal
NCT ID: NCT04864561 Org: User:
Start: 04/26/21 End: 03/13/23 Due: 03/13/24

Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

Phase: N/A Priority: Normal
NCT ID: NCT04956224 Org: User:
Start: 08/09/21 End: 11/18/22 Due: 11/18/23

Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47

Phase: N/A Priority: Normal
NCT ID: NCT00873431 Org: User:
Start: 03/31/09 End: 02/28/10 Due: 02/28/11